Humacyte, Inc. (HUMA): Results of Operations and Financial Condition
Humacyte, Inc. (HUMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update – Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis acces
How this was made
The 30-second read
Why it matters
Key new disclosures are the V012 Phase 3 interim efficacy/safety results in women, the planned 2H 2026 supplemental BLA filing for ATEV, and FDA IND acceptance for the CTEV CABG first-in-human study with Phase 2a planned for Q3 2026.
Market read
Traders can update probabilities around Humacyte’s regulatory path for dialysis access (sBLA timing) and near-term clinical execution for coronary indications (Phase 2a start).
What to watch
Commercial execution for Symvess is still early, with Q2 sales only $0.4M, so valuation may hinge more on regulatory outcomes than current revenue traction.
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
Humacyte reported higher Symvess commercial sales and significant clinical and regulatory progress, while cost of goods sold exceeded commercial sales and included inventory reserves and unused-capacity costs. The company also raised capital and implemented a workforce restructuring.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Symvess commercial sales, three monthsother | $0.4 million | – | – |
| Symvess commercial sales, six monthsother | $0.9 million | – | – |
| Contract revenue, three monthsother | no meaningful contract revenue | – | – |
| Contract revenue, six monthsother | no meaningful contract revenue | – | – |
| Cost of goods sold, three monthsother | $1.2 million | – | – |
| Cost of goods sold, six monthsother | $3.3 million | – | – |
| Cost of units recorded as sales revenue, three monthsother | $0.2 million | – | – |
| Inventory reserve, three monthsother | $0.7 million | – | – |
| Cost of units recorded as sales revenue, six monthsother | $0.5 million | – | – |
| Inventory reserve, six monthsother | $2.3 million | – | – |
| Research and development expenses, three monthsother | $18.1 million | – | – |
| Research and development expenses, six monthsother | $37.6 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Symvess commercial salesThe company said it focused the second quarter on rebuilding its commercial effort for Symvess, including refined introductory pricing incentive programs, professional-to-professional education, and a streamlined value analysis committee process. | $0.4 million | – | – |
What drove it
- In a pre-specified interim analysis of the first 80 patients from the V012 Phase 3 study, women who received the ATEV achieved an average of 91 more catheter-free days than those receiving AV fistula, with p=0.00070.
- Patients receiving the ATEV had 6 infections per 100 patient years compared with 23 per 100 patient years for patients who received an AV fistula.
- Humacyte plans to submit a supplemental Biologics License Application to the FDA in the second half of 2026.
- The FDA accepted the IND application for a first-in-human clinical study of the CTEV in coronary artery bypass grafting, and Humacyte plans to initiate a Phase 2a study during the current quarter.
- Humacyte completed the first large-scale manufacturing lot of CTEV in its commercial-scale production facilities.
- Humacyte implemented a restructuring of its workforce to reduce total headcount by approximately 45 employees through a reduction in force and by deferment of planned hires.
- Humacyte estimates net savings due to the workforce reductions and operating cost reductions, net of termination severance and benefits, totaling approximately $14.3 million during 2026.
Concerns
- Cost of goods sold was $1.2 million in the second quarter of 2026, including a $0.7 million inventory reserve and overhead related to unused production capacity.
- There was no meaningful contract revenue in the three or six months ended June 30, 2026 due to completion of a research collaboration project in the prior year.
- For uses other than FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
- The CTEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
What to watch
- Submission of the planned supplemental Biologics License Application for dialysis access in the second half of 2026.
- Initiation of the planned Phase 2a CTEV study in coronary artery bypass grafting during the current quarter.
- Symvess hospital approvals, utilization, and revenue growth following the commercial-team remodeling and adoption initiatives.
- The Israel Ministry of Health review of the Symvess Marketing Authorization Application, for which it set a 180-working-day review period.
- Execution of the estimated approximately $14.3 million of 2026 net savings from workforce and operating cost reductions.
Balance sheet and cash flow
- In June 2026 Humacyte raised aggregate gross proceeds of $57.5 million from a public offering of its common stock.
Analysis
Humacyte reported second-quarter Symvess commercial sales of $0.4 million, compared with $0.1 million in the second quarter of 2025. For the six months ended June 30, 2026, commercial sales were $0.9 million compared with $0.2 million for the six months ended June 30, 2025. The company attributed its commercial focus to a rebuilt sales effort, pricing incentives, professional education, and a streamlined value analysis committee process. Contract revenue was not a contributor, as Humacyte reported no meaningful contract revenue in the three- or six-month periods following completion of a research collaboration project in the prior year.
Management, verbatim
Results from this trial exceeded our expectations, and our acellular tissue engineered vessel (ATEV) outperformed autologous arteriovenous (AV) fistula, the current standard of care for patients on dialysis.
Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte
We intentionally focused our second quarter on rebuilding our commercial effort for Symvess, along with implementing an enterprise-wide transformation.
Jim Mercadante, Chief Commercial Officer of Humacyte
Not in the filing
stated, not guessed- Total revenue for the second quarter of 2026 and prior-year comparison were not provided in the supplied filing excerpt.
- Gross profit and gross margin were not provided in the supplied filing excerpt.
- Selling, general and administrative expenses were not provided in the supplied filing excerpt.
- Operating income or loss was not provided in the supplied filing excerpt.
- Net income or loss was not provided in the supplied filing excerpt.
- GAAP and non-GAAP earnings per share were not provided in the supplied filing excerpt.
- Non-GAAP financial measures were not provided in the supplied filing excerpt.
- Operating cash flow and free cash flow were not provided in the supplied filing excerpt.
- Period-end cash, cash equivalents, investments, debt, and liquidity runway were not provided in the supplied filing excerpt.
- Share repurchases and dividends were not provided in the supplied filing excerpt.
- Forward financial guidance for revenue, gross margin, operating expenses, tax rate, or other financial measures was not provided.
- Prior-quarter comparisons for reported financial metrics were not provided.
- Percentage year-over-year and quarter-over-quarter changes for the reported financial metrics were not provided.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This SEC 8-K (Item 2.02) accompanies Humacyte’s Q2 2026 financial results and pipeline/business update, including dialysis access and coronary vessel programs.
Ticker impact
Humacyte reports V012 Phase 3 interim results in female dialysis patients and says it will file a supplemental BLA in 2H 2026.
Bias to upside on any market reaction, with follow-through risk tied to FDA review timing and durability of Phase 3 data.
This 8-K discloses new, decision-relevant clinical and regulatory milestones (sBLA timing, FDA IND acceptance for CTEV, and Phase 2a start plan) plus a small Symvess sales datapoint.
Market effects
Could strengthen sentiment around vascular access and bioengineered tissue platforms, potentially improving risk appetite for similar late-stage biotech programs.
Limited direct regional spillover; primary impact is on US-listed biotech sentiment.
Moderate, as dialysis access and CABG conduit innovation are globally relevant but the disclosed milestones are US-regulatory driven.
Counterpoint
Interim analysis of the first 80 patients may not fully de-risk the full Phase 3 readout, and FDA acceptance does not guarantee approval or timeline.
Key entities
- companyHumacyte, Inc.
Commercial-stage biotech developing bioengineered human tissues; subject of the 8-K and pipeline update.
- clinical_programV012 Phase 3 (ATEV)
Dialysis access Phase 3 interim analysis in female patients; ATEV outperformed AV fistula on catheter-free days and showed fewer infections per 100 patient years.
- regulatorFDA
Accepted IND for CTEV first-in-human study and is the target agency for the planned supplemental BLA filing.
- clinical_programCTEV (CABG)
Coronary tissue engineered vessel program; IND accepted and Phase 2a planned for CABG during Q3 2026.
- productSymvess
Humacyte’s commercial product; Q2 2026 sales disclosed as $0.4M vs $0.1M in 2025.
